In these cases, neoadjuvant endocrine therapy (NET) has demonstrated promising clinical response rates in HR+ HER2– breast cancer and may enhance breast conservation eligibility while minimizing the need for extensive axillary surgery and avoiding systemic toxicity associated with chemotherapy. The gene discussed is ERBB2; the disease is breast carcinoma.